WO2011075471A3 - Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders - Google Patents

Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders Download PDF

Info

Publication number
WO2011075471A3
WO2011075471A3 PCT/US2010/060263 US2010060263W WO2011075471A3 WO 2011075471 A3 WO2011075471 A3 WO 2011075471A3 US 2010060263 W US2010060263 W US 2010060263W WO 2011075471 A3 WO2011075471 A3 WO 2011075471A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mediated disorders
natriuretic peptide
type natriuretic
agonists
Prior art date
Application number
PCT/US2010/060263
Other languages
French (fr)
Other versions
WO2011075471A2 (en
Inventor
Frank Osterkamp
Heiko Hawlisch
Gerd Hummel
Tobias Knaute
Ulf Reimer
Ulrich Reineke
Bernadett Simon
Uwe Richter
Edgar Specker
Markus Woischnik
Original Assignee
Alcon Research, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Research, Ltd. filed Critical Alcon Research, Ltd.
Publication of WO2011075471A2 publication Critical patent/WO2011075471A2/en
Publication of WO2011075471A3 publication Critical patent/WO2011075471A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are novel compounds having NPR-B agonistic activity. Preferred compounds are linear peptides containing 8-13 conventional or non-conventional L- or D- amino acid residues connected to one another via peptide bonds. Also disclosed are methods of treating C-type natriuretic peptide (CNP)-mediated disorders, including glaucoma and/or elevated intraocular pressure, in a subject using pharmaceutical compositions that include a novel NPR-B agonist as described herein.
PCT/US2010/060263 2009-12-18 2010-12-14 Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders WO2011075471A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28776809P 2009-12-18 2009-12-18
US61/287,768 2009-12-18

Publications (2)

Publication Number Publication Date
WO2011075471A2 WO2011075471A2 (en) 2011-06-23
WO2011075471A3 true WO2011075471A3 (en) 2012-01-05

Family

ID=44167923

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/060263 WO2011075471A2 (en) 2009-12-18 2010-12-14 Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders

Country Status (1)

Country Link
WO (1) WO2011075471A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108653715A (en) * 2011-12-16 2018-10-16 卡乐斯治疗公司 The method and purposes of ANP, BNP and CNP related peptide and its derivative for treating retinal disorder and disease
WO2013161895A1 (en) * 2012-04-25 2013-10-31 第一三共株式会社 Bone repair promoter
CN107405409B (en) * 2015-01-09 2022-03-22 阿森迪斯药物生长障碍股份有限公司 CNP prodrugs
MX2018008061A (en) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Cnp prodrugs with large carrier moieties.
AU2017205694B2 (en) 2016-01-08 2022-05-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
KR20180100624A (en) 2016-01-08 2018-09-11 아센디스 파마 그로우쓰 디스오더스 에이/에스 Controlled-release CNP agonists with increased NEP stability
IL259658B2 (en) 2016-01-08 2024-06-01 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with reduced side-effects
AU2017205688C1 (en) 2016-01-08 2022-03-10 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
CA3007982C (en) 2016-01-08 2023-12-19 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low initial npr-b activity
PL3464336T3 (en) 2016-06-01 2022-05-16 Athira Pharma, Inc. Compounds
BR112019005351A2 (en) 2016-09-29 2019-06-11 Ascendis Pharma Growth Disorders As combination therapy with controlled release cnp agonists
EP3576770A1 (en) * 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
WO2009067639A2 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
WO2011038066A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US7297709B2 (en) 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
TW200640443A (en) 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050113286A1 (en) * 2002-03-18 2005-05-26 Schreiner George F. Methods for treating congestive heart failure
WO2009067639A2 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of c-type natriuretic peptide
WO2011038066A2 (en) * 2009-09-25 2011-03-31 Alcon Research, Ltd. Novel npr-b agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NISHIKIMI T ET AL: "The role of natriuretic peptides in cardioprotection", CARDIOVASCULAR RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 69, no. 2, 1 February 2006 (2006-02-01), pages 318 - 328, XP025011217, ISSN: 0008-6363, [retrieved on 20060201], DOI: 10.1016/J.CARDIORES.2005.10.001 *
SCOTLAND R S ET AL: "C-type natriuretic peptide in vascular physiology and disease", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 105, no. 2, 1 February 2005 (2005-02-01), pages 85 - 93, XP027636139, ISSN: 0163-7258, [retrieved on 20050201] *

Also Published As

Publication number Publication date
WO2011075471A2 (en) 2011-06-23

Similar Documents

Publication Publication Date Title
WO2011075471A3 (en) Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
WO2011038066A3 (en) Novel npr-b agonists
WO2011038061A3 (en) Novel npr-b agonists
WO2010135541A3 (en) Variants of c-type natriuretic peptide
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
WO2009067639A3 (en) Variants of c-type natriuretic peptide
MY193457A (en) Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2009011544A3 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
WO2010120476A3 (en) N-terminus conformationally constrained glp-1 receptor agonist compounds
NZ598600A (en) Therapeutic agent for rhinitis
MX344559B (en) Pegylated recombinant human growth hormone compounds.
WO2010024608A3 (en) Composition containing collagen peptide for improving skin care
MX2009012675A (en) Reconstituted surfactants having improved properties.
MX2018014023A (en) Mic-1 compounds and use thereof.
WO2012142320A8 (en) Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
WO2010130832A3 (en) Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
PH12019550241A1 (en) Mic-1 compounds and uses thereof
WO2009007714A3 (en) Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
WO2009020643A3 (en) Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue
WO2013096868A3 (en) Saposin-a derived peptides and uses thereof
EP2664343A3 (en) Suppression of cancer
MY200975A (en) "Compositions Comprising Amino acids for use in the Treatment of Mitochondrial Dysfunction-Related Diseases"
MX2012003924A (en) Synthetic myostatin peptide antagonists.
WO2012109561A3 (en) Tripeptide compositions and methods for treatment of diabetes
CA2839298C (en) Anti-inflammatory pharmaceutical products

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10835271

Country of ref document: EP

Kind code of ref document: A1

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10835271

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10835271

Country of ref document: EP

Kind code of ref document: A2